Incidence, risk factors, and outcomes of endoscopic sinus surgery after endoscopic skull-base surgery.
Ravi R ShahIvy W MainaNeil N PatelVasiliki TriantafillouAlan D WorkmanEdward Cheng-Lung KuanCharles Ching Lick TongMichael A KohanskiBert W O'MalleyNithin D AdappaJames N PalmerPublished in: International forum of allergy & rhinology (2020)
A significant proportion of patients develop clinically significant sinusitis after endoscopic SBS for neoplasms with combined sinonasal and skull base involvement and may benefit from rESS. Intervention occurred, on average, 3.5 years after initial tumor resection. Malignant pathology, radiation therapy, and chemotherapy correlate with need for rESS.
Keyphrases
- risk factors
- ultrasound guided
- minimally invasive
- radiation therapy
- end stage renal disease
- coronary artery bypass
- randomized controlled trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- surgical site infection
- prognostic factors
- locally advanced
- squamous cell carcinoma
- adipose tissue
- skeletal muscle
- patient reported
- glycemic control